Literature DB >> 16773616

Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome.

Deborah A Hall1, Elizabeth Berry-Kravis, Randi J Hagerman, Paul J Hagerman, Cathlin D Rice, Maureen A Leehey.   

Abstract

There is no established treatment for the neurological features of the recently discovered fragile X-associated tremor/ataxia syndrome (FXTAS). Fifty-six patients with FXTAS completed a questionnaire to determine whether any medications had been effective for neurological symptoms. Of 11 subjects with definite FXTAS, 8 (70%) were on medications for their neurological symptoms, whereas most subjects with possible or probable FXTAS, 31 (70%) of 45 subjects, were not on medications. Although no therapy was uniformly effective for intention tremor, ataxia, Parkinsonism, memory loss, or anxiety, some subjects with intention tremor or Parkinsonism reported improvement with medications frequently used in other movement disorders. Overall, all 22 subjects on medications reported improvement in one or more symptoms. Lack of insight, recall bias, and cognitive impairment may have resulted in an underestimation of the beneficial effect of medical therapy. This study suggests that patients with FXTAS can derive improvement from medication treatment for some of their symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773616     DOI: 10.1002/mds.21001

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

Review 1.  [Fragile X associated tremor/ataxia syndrome: its clinical presentation, pathology, and treatment].

Authors:  M J Salcedo-Arellano; R J Hagerman; V Martinez-Cerdeno
Journal:  Rev Neurol       Date:  2019-03-01       Impact factor: 0.870

2.  A Novel Clinical Phenotype of Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  Gary Alvarez Bravo; Jose Manuel Fernández-Carril; Ignacio López-Zuazo; Antonio Yusta Izquierdo; Tapan Abrol; Omar Alsinaidi
Journal:  Mov Disord Clin Pract       Date:  2018-07-19

3.  Risk Factors for Cognitive Impairment in Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  Andreea L Seritan; Kyoungmi Kim; Ian Benjamin; Ioana Seritan; Randi J Hagerman
Journal:  J Geriatr Psychiatry Neurol       Date:  2016-09-21       Impact factor: 2.680

4.  PSYCHIATRIC DISORDERS ASSOCIATED WITH FXTAS.

Authors:  Andreea L Seritan; Melina Ortigas; Stefan Seritan; James A Bourgeois; Randi J Hagerman
Journal:  Curr Psychiatry Rev       Date:  2013

5.  COGNITIVE DYSFUNCTION IN FMR1 PREMUTATION CARRIERS.

Authors:  Andreea Seritan; Jennifer Cogswell; Jim Grigsby
Journal:  Curr Psychiatry Rev       Date:  2013-02

6.  Female CGG knock-in mice modeling the fragile X premutation are impaired on a skilled forelimb reaching task.

Authors:  Amanda A Diep; Michael R Hunsaker; Richard Kwock; Kyoungmi Kim; Rob Willemsen; Robert F Berman
Journal:  Neurobiol Learn Mem       Date:  2011-12-21       Impact factor: 2.877

7.  Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease.

Authors:  Andreea L Seritan; Danh V Nguyen; Sarah Tomaszewski Farias; Ladson Hinton; Jim Grigsby; James A Bourgeois; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568

Review 8.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

Review 9.  [Fragile X-associated tremor/ataxia syndrome].

Authors:  C Finke; R Horváth; E Holinski-Feder; C J Ploner
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

Review 10.  Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment.

Authors:  Maureen A Leehey
Journal:  J Investig Med       Date:  2009-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.